Skip to main content

Table 3 Results of the cost-utility analysis

From: Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings

Treatment arm

Cost, €

Incremental cost, €

LYG

Incremental LYG

QALY gained

Incremental QALY gained

ICER, €/QALY

Optimal medical treatment

18,944

 

4.46

 

2.91

  

Percutaneous mitral valve repair

36,785

17,841

5.87

1.41

4.06

1.15

15,533

  1. ICER – incremental cost-effectiveness ratio; LYG – life years gained; QALY – quality-adjusted life years
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us